國藥股份、國藥一致快速拉昇 國藥集團旗下滅活疫苗將進入臨牀試驗
格隆匯4月13日丨國藥集團旗下的國藥股份和國藥一致出現快速拉昇走勢,目前分別漲9%和4%,天壇生物也出現一波拉昇,目前漲超1%。午間消息顯示,繼陳薇團隊後,中國又一款新冠肺炎疫苗將進入臨牀試驗階段。4月13日,由國藥集團中國生物武漢生物製品研究所有限責任公司研發的新型冠狀病毒(COVID-19)滅活疫苗(Vero細胞)Ⅰ/Ⅱ期臨牀試驗在中國臨牀試驗註冊中心正處於“通過審核”預註冊狀態。根據公開信息,這是繼中國工程院院士、軍事科學院軍事醫學研究院研究員陳薇團隊之後,中國第二個註冊進入臨牀試驗的新型冠狀病毒疫苗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.